| Question 1: After prostate brachytherapy, the most common site of recurrence is: |
| Reference: | Arrayeh E, Westphalen A, Kurhanewicz J. Does local recurrence of prostate cancer after radiation
therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat
Oncol Biol Phys 2012. |
| Choice A: | At the site of extraprostatic extension. |
| Choice B: | Within the regional lymph nodes. |
| Choice C: | Near the site of the dominant intraprostatic lesion. |
| Choice D: | All of the above |
| Question 2: In fiducial point-based registration, the target registration error is calculated based on the postregistration
position of the fiducial points used to determine the transformation. |
| Reference: | J. M. Fitzpatrick and J. B. West, "The distribution of target registration error in rigid-body point-based
registration," in IEEE Transactions on Medical Imaging, vol. 20, no. 9, pp. 917-927, Sept. 2001, doi:
10.1109/42.952729. |
| Choice A: | True |
| Choice B: | False |
| Question 3: The addition of radiomic measures used in conjunction with pathology compared with pathology
alone could potentially allow better characterization of the spatial heterogeneity of cancer |
| Reference: | Rogers W, Thulasi Seetha S, Refaee TAG, Lieverse RIY, Granzier RWY, Ibrahim A, Keek SA, Sanduleanu S,Primakov SP, Beuque MPL, Marcus D, van der Wiel AMA, Zerka F, Oberije CJG, van Timmeren JE,Woodruff HC, Lambin P. Radiomics: from qualitative to quantitative imaging. Br J Radiol. 2020 Apr;93(1108):20190948. doi: 10.1259/bjr.20190948. Epub 2020 Feb 26. PMID: 32101448; PMCID: PMC7362913. |
| Choice A: | True |
| Choice B: | False |
| Question 4: The addition of radiomic measures used in conjunction with pathology compared with pathology alone could potentially improve the positive predictive value of screening and reduce false positives in screening. |
| Reference: | Rogers W, Thulasi Seetha S, Refaee TAG, Lieverse RIY, Granzier RWY, Ibrahim A, Keek SA, Sanduleanu S,
Primakov SP, Beuque MPL, Marcus D, van der Wiel AMA, Zerka F, Oberije CJG, van Timmeren JE,
Woodruff HC, Lambin P. Radiomics: from qualitative to quantitative imaging. Br J Radiol. 2020
Apr;93(1108):20190948. doi: 10.1259/bjr.20190948. Epub 2020 Feb 26. PMID: 32101448; PMCID:
PMC7362913. |
| Choice A: | True |
| Choice B: | False |
| Question 5: Quantitative multiplex biomarker imaging could help reduce overtreatment of cancer and allow
avoiding treatments that are ineffective |
| Reference: | Cheung AM, Wang D, Liu K, Hope T, Murray M, Ginty F, Nofech-Mozes S, Martel AL, Yaffe MJ.
Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker
spatial heterogeneity within breast cancer subtypes. Breast Cancer Res. 2021 Dec 18;23(1):114. doi:
10.1186/s13058-021-01475-y. PMID: 34922607; PMCID: PMC8684264.
Leandersson P, Åkesson A, Hedenfalk I, Malander S, Borgfeldt C (2020) A multiplex biomarker assay
improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. PLoS ONE 15(10):
e0240418. https://doi.org/10.1371/journal.pone.0240418 |
| Choice A: | True |
| Choice B: | False |
| Question 6: Quantitative multiplex biomarker imaging is based on DNA or RNA sequencing |
| Reference: | Cheung AM, Wang D, Liu K, Hope T, Murray M, Ginty F, Nofech-Mozes S, Martel AL, Yaffe MJ.
Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker
spatial heterogeneity within breast cancer subtypes. Breast Cancer Res. 2021 Dec 18;23(1):114. doi:
10.1186/s13058-021-01475-y. PMID: 34922607; PMCID: PMC8684264.
Leandersson P, Åkesson A, Hedenfalk I, Malander S, Borgfeldt C (2020) A multiplex biomarker assay
improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. PLoS ONE 15(10):
e0240418. https://doi.org/10.1371/journal.pone.0240418 |
| Choice A: | True |
| Choice B: | False |
